Tirzepatide SURMOUNT-OSA trial and cardiometabolic subanalysis

April 21, 2026A Podcast on Tirzepatide SURMOUNT-OSA trial and cardiometabolic subanalysis.A portion of the ATS SRN 360 high impact articles from the past year.• Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity – Presented by Richard J Schwab, MD - Perelman School of Medicine, University of Pennsylvania, Philadelphia; the Division of Sleep and Circadian Disorders• Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.Presented by Scott A. Sands, Ph.D - Brigham and Women’s Hospital and Harvard Medical School in Boston, MassachusettsModerated by Chana Chin, MD from CHOC Children's/Rady's Children's Health and Bradon Nokes, MD from University of California, San Diego00:00 — Podcast Introduction & Presentation Overview 00:15 — Tirzepatide for Obstructive Sleep Apnea and Obesity 00:47 — SURMOUNT-OSA Trial Design and Patient Population 01:44 — Primary Endpoints and Secondary Outcome Measures 02:53 — Baseline Demographics and Clinical Characteristics 03:52 — Weight Loss Effects and Sleep Apnea Improvement Results 05:52 — Cardiometabolic Outcomes, Blood Pressure, and Safety Findings 08:40 — Clinical Discussion: Prescribing Tirzepatide in OSA Practice 12:03 — Secondary Analysis of Cardiometabolic Risk Mediation 20:08 — Long-Term Use, Mechanisms of Action, and Audience Q&A